MPM Raises $400m To Build Early-Stage Biotechs
Executive Summary
The venture capitalist builds biotechs from scratch and with this latest fund, MPM is looking to add to its sector-leading record of 49 FDA-approved drugs and over 100 IPOs and acquisitions.